Pharmaron forecasts revenue growth but profit decline

Pharmaron Beijing anticipates interim 2025 revenue to increase 13% to 16% year-on-year, reaching 6.33 billion to 6.50 billion yuan.

Net profit attributable to owners is estimated to decrease 36% to 39%, largely due to reduced non-recurring gains compared to the prior year. However, non-IFRS adjusted net profit is projected to grow 6% to 11%.